In a report released today, Martin Comtesse from Jefferies maintained a Buy rating on DocMorris (DOCM – Research Report), with a price target of CHF39.00.
Martin Comtesse has given his Buy rating due to a combination of factors including the company’s strategic financial maneuvers and growth prospects. DocMorris is planning a capital raise of CHF 200 million in the second quarter, which is expected to strengthen its balance sheet and support its growth initiatives in the prescription drug market.
Furthermore, the company has indicated a promising growth trajectory for its German prescription segment, projecting a 50% year-over-year increase. This anticipated growth, alongside the refinancing of its existing convertible bonds, positions DocMorris well for future expansion, making it an attractive investment opportunity.
According to TipRanks, Comtesse is a 2-star analyst with an average return of 0.2% and a 45.96% success rate.
In another report released on February 28, Hauck & Aufhaeuser also maintained a Buy rating on the stock with a CHF60.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com